Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13224367 | 0.89 | MAPT (0.38) | MAPTALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL8447826 | 0.89 | — | — | |
| SCHEMBL6402662 | 0.84 | MAPT (0.38) | MAPTALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL12332811 | 0.83 | MAPT (0.53) | MAPTALDH1A1 | |
| SCHEMBL15200245 | 0.83 | MAPT (0.53) | MAPTALDH1A1 | |
| SCHEMBL1286694 | 0.83 | MAPT (0.53) | MAPTALDH1A1 | |
| SCHEMBL12986878 | 0.81 | ALDH1A1 (0.42) | MAPTALDH1A1NPC1 | |
| SCHEMBL13400952 | 0.81 | MAPT (0.36) | MAPTALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL13195804 | 0.81 | ALDH1A1 (0.42) | MAPTALDH1A1NPC1 | |
| SCHEMBL20599687 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3645516-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Janssen Pharmaceutica NV (BE) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019001420-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-03 | — | — | WO | disclosed |